The role of oral anticoagulants in tumor biology

Seminars in Thrombosis and Hemostasis

Volumn 33, Issue 7, 2007, Pages 695-698

  Weitz, Ilene C ^a   Liebman, Howard A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Anticoagulation; Cancer; Prothrombin; Vitamin K; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN; THROMBIN INHIBITOR; WARFARIN;

ANTICOAGULATION; CANCER SURVIVAL; CARCINOGENESIS; DRUG EFFECT; HEMOSTASIS; HUMAN; INCIDENCE; LONG TERM CARE; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM;

ANIMALS; ANTICOAGULANTS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASMS; SURVIVAL RATE; VITAMIN K; WARFARIN;

EID: 36348941842     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-991537     Document Type: Review

References (26)

1. Billroth T. Lectures on Surgical Pathology and Therapeutics (trans. from the 8th ed.). London: New Sydenham Society; 1878
2. Agostino D, Cliffton EE, Girolami A. Effect of prolonged Coumadin treatment on the production of pulmonary metastases in the rat. Cancer 1966;19:284-288
3. Ryan JJ, Ketcham AS, Wexler H. Warfarin treatment of mice bearing autochthonous tumors: effect on spontaneous metastases. Science 1968;162:1493-1494
4. Lione A, Bosmann HB. The inhibitory effect of heparin and warfarin treatments on the intravascular survival of B16 melanoma cells in syngeneic C57 mice. Cell Biol Int Rep 1978;2:81-86
5. Brown JM. A study of the mechanism by which anticoagulation with warfarin inhibit blood-borne metastases. Cancer Res 1973;33:1217-1224
6. Thornes RD, Edlow DW, Wood S Jr. Inhibition of locomotion of cancer cells in vivo by anticoagulant therapy. I. Effects of sodium warfarin on V2 cancer cells, granulocytes, lymphocytes and macrophages in rabbits. Johns Hopkins Med J 1968;123:305-316
7. Higashi H, Heidelberger C. Lack of effect of warfarin (NSC-59813) alone or in combination with 5-fluorouracil (NSC-19893) on primary and metastatic L1210 leukemia and adenocarcinoma 755. Cancer Chemother Rep 1971;55:29-33
8. Chang JC, Hall TC. In vitro effect of sodium warfarin on DNA and RNA synthesis of mouse L1210 leukemic cells and walker tumor cells. Oncology 1973;28:232-237
9. Thornes RD. Oral anticoagulant therapy of human cancer. J Med 1974;5:83-91
10. Michaels L. The incidence and course of cancer in patients receiving anticoagulant therapy. Retrospective and prospective studies. J Med 1974;5:98-106
11. Hoover HC, Ketcham AS, Millar RC, Gralnick HR. Osteosarcoma: improved survival with anticoagulation and amputation. Cancer 1978;41:2475-2480
12. Zacharski LR, Henderson WG, Rickles FR, et al. Rationale and experimental design for the VA Cooperative Study of anticoagulation (warfarin) in the treatment of cancer. Cancer 1979;44:732-741
13. Zacharski LR, Henderson WG, Rickles FR, et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck and prostate. Cancer 1984;53:2046-2052
14. Maurer LH, Herndon JE, Hollis DR, et al. Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. J Clin Oncol 1997;15:3378-3387
15. Chahinian AP, Propert KJ, Ware JH, et al. A randomized tirai of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol 1989;7:993-1002
16. Levine M, Hirsh J, Gent M, et al. Double-blind randomized trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994;343:886-889
17. Daly L. The first international urokinase/warfarin trial in colorectal cancer. Clin Exp Metastasis 1991;9:3-11
18. Michaels L. Cancer incidence and mortality in patients having anticoagulant therapy. Lancet 1964;2:832-835
19. Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. N Engl J Med 2000;342:1953-1958
20. Taliani MR, Agnelli G, Prandoni P, et al. Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation. J Thromb Haemost 2003;1:1730-1733
21. Schulman S, Lindmarker P. Vitamin K antagonists and cancer: rebuttal. J Thromb Haemost 2004;2:377-378
22. Taliani MR, Agnelli G, Prandoni P. Vitamin K antagonists and cancer: reply to rebuttal. J Thromb Haemost 2004;2(2):378-379
23. Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004;22(10):1944-1948
24. Klerk CPW, Smorenburg SM, Otten JMMB, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23:2130-2135
25. Lee AYY, Julian JA, Levine MN, et al. Long-term treatment with dalteparin low-molecular weight heparin (LMWH) may improve survival in patients with non-metastatic malignancy and venous thromboembolism. J Clin Oncol 2005;23:2123-2129
26. Altinbas M, Colkun HS, Er O, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004;2:1266-1271